Related Experiment Video
Updated: Jul 7, 2026
06:06
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function
The Journal of Clinical Investigation
|February 1, 1985
Summary
New polyethylene glycol (PEG)-streptokinase adducts show reduced antigenicity and prolonged plasma clearance. These modified streptokinases may offer therapeutic potential for treating thrombotic disorders.
Area of Science:
- Biochemistry
- Protein Chemistry
- Pharmacology
Background:
- Streptokinase is a thrombolytic agent used to treat thrombotic disorders.
- Its clinical use is limited by immunogenicity and rapid clearance.
- Polyethylene glycol (PEG)ylation is a strategy to improve protein drug properties.
Purpose of the Study:
- To synthesize and characterize novel covalent polyethylene glycol (PEG)-streptokinase adducts.
- To evaluate the enzymatic activity, stability, antigenicity, and in vivo clearance of these adducts.
- To explore the potential therapeutic applications of PEG-streptokinase adducts in thrombotic disorders.
Main Methods:
- Synthesis of PEG-streptokinase adducts using carbonyldiimidazole activation.
- Kinetic analysis (Km, kcat) of plasminogen activation.
- Assessment of plasmin activity and resistance to plasmin degradation.
- Measurement of antibody binding and in vivo plasma clearance in mice.
Main Results:
- PEG-streptokinase adducts exhibited comparable Km values to native streptokinase, with some reduction in kcat.
- PEG-2-streptokinase and PEG-4-streptokinase showed increased activity and resistance to plasmin cleavage.
- Adducts demonstrated >95% reduction in binding to anti-streptokinase antibodies.
- In vivo studies showed slower clearance of PEG-streptokinase-plasmin complexes compared to unmodified streptokinase-plasmin.
Conclusions:
- PEG-streptokinase adducts possess significantly reduced antigenicity and prolonged plasma half-life.
- These modified streptokinases retain enzymatic activity and exhibit enhanced stability.
- PEG-streptokinase complexes represent a promising strategy for developing improved thrombolytic therapies.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
01:09Cytoskeletal Linker Proteins - Plakins
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.